Xibmed 90 Tablet

This selective action offers an improved gastrointestinal safety profile compared to non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). Xibmed 90 Tablet is administered orally, with dosage and duration tailored to the patient’s condition and response to therapy. It is contraindicated in patients with known hypersensitivity to Etoricoxib, active peptic ulceration, severe hepatic or renal impairment, and established cardiovascular disease due to potential increased risk of thrombotic events.

Caution is advised in patients with hypertension, heart failure, or risk factors for cardiovascular disease. Common adverse effects include headache, dizziness, hypertension, and gastrointestinal discomfort. Patients should be monitored regularly during prolonged therapy to assess efficacy and detect any adverse reactions.